UA73109C2 - Method for generating polyclonal antibodies and method for generating monoclonal antibodies specifically incorporated into polypeptide phosphorylated to definite amino acid - Google Patents
Method for generating polyclonal antibodies and method for generating monoclonal antibodies specifically incorporated into polypeptide phosphorylated to definite amino acid Download PDFInfo
- Publication number
- UA73109C2 UA73109C2 UA2001075343A UA2001075343A UA73109C2 UA 73109 C2 UA73109 C2 UA 73109C2 UA 2001075343 A UA2001075343 A UA 2001075343A UA 2001075343 A UA2001075343 A UA 2001075343A UA 73109 C2 UA73109 C2 UA 73109C2
- Authority
- UA
- Ukraine
- Prior art keywords
- polypeptide
- amino acid
- phosphorylated
- antibodies
- stage
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 103
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 88
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 54
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 28
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims abstract description 20
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 17
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229950006137 dexfosfoserine Drugs 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 11
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims abstract description 10
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 230000003278 mimic effect Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000002649 immunization Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 108060003552 hemocyanin Proteins 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 101100038123 Danio rerio rorab gene Proteins 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229960001005 tuberculin Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 238000001261 affinity purification Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 230000000405 serological effect Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract description 26
- 102000036639 antigens Human genes 0.000 abstract description 26
- 108091007433 antigens Proteins 0.000 abstract description 26
- 230000026731 phosphorylation Effects 0.000 abstract description 16
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 16
- 230000001900 immune effect Effects 0.000 abstract description 7
- 238000010561 standard procedure Methods 0.000 abstract description 7
- 230000000890 antigenic effect Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 102000007982 Phosphoproteins Human genes 0.000 description 7
- 108010089430 Phosphoproteins Proteins 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- -1 phospho Chemical class 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000009822 protein phosphorylation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001190694 Muda Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 241000269350 Anura Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 101001130304 Mus musculus Ras-related protein Rab-23 Proteins 0.000 description 1
- 241000424792 Perionyx excavatus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/236,415 US6309863B1 (en) | 1999-01-25 | 1999-01-25 | Methods for generating phosphorylation site-specific immunological reagents |
| PCT/US2000/001796 WO2000043422A1 (en) | 1999-01-25 | 2000-01-25 | Methods for generating phosphorylation site-specific immunological reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73109C2 true UA73109C2 (en) | 2005-06-15 |
Family
ID=22889404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001075343A UA73109C2 (en) | 1999-01-25 | 2000-01-25 | Method for generating polyclonal antibodies and method for generating monoclonal antibodies specifically incorporated into polypeptide phosphorylated to definite amino acid |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6309863B1 (no) |
| EP (1) | EP1147137B9 (no) |
| JP (1) | JP3891542B2 (no) |
| AT (1) | ATE324382T1 (no) |
| AU (1) | AU767969B2 (no) |
| BR (1) | BR0008977A (no) |
| CA (1) | CA2360511C (no) |
| DE (1) | DE60027542T2 (no) |
| HU (1) | HUP0105309A3 (no) |
| IL (2) | IL144471A0 (no) |
| MX (1) | MXPA01007323A (no) |
| NO (1) | NO20013636L (no) |
| NZ (1) | NZ512868A (no) |
| UA (1) | UA73109C2 (no) |
| WO (1) | WO2000043422A1 (no) |
| ZA (1) | ZA200105520B (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
| WO2003057238A1 (en) * | 2001-12-28 | 2003-07-17 | Oregon Health & Science University | Agents that recognize src when phosphorylated at serine 17 |
| US7452676B2 (en) * | 2003-01-16 | 2008-11-18 | Uti Limited Partnership | Monoclonal antibodies to RNA binding protein GW182 |
| US20090081659A1 (en) * | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| JP2011518126A (ja) * | 2008-03-25 | 2011-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ＩＫＫｉ阻害剤の処置方法およびスクリーニング方法、ならびに関連するＩＫＫｉ診断方法 |
| US8445706B2 (en) * | 2008-09-05 | 2013-05-21 | Board Of Trustees Of Northern Illinois University | Unnatural amino acids capable of covalently modifying protein phosphatases and their use as general and specific inhibitors and probes |
| WO2011149909A2 (en) * | 2010-05-24 | 2011-12-01 | Hunt Donald F | Class i mhc phosphopeptides for cancer immunotherapy and diagnosis |
| EP2675275B1 (en) | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| US10640535B2 (en) | 2012-05-25 | 2020-05-05 | Agenus Inc. | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies |
| AU2013308409A1 (en) | 2012-08-31 | 2015-03-26 | University Of Birmingham | Target peptides for immunotherapy and diagnostics |
| EP4088737A3 (en) | 2012-09-05 | 2023-02-08 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
| EP2991647B1 (en) | 2013-05-02 | 2019-04-24 | The Regents Of The University Of Michigan | Deuterated amlexanox with improved metabolic stability |
| EP3137100B1 (en) | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
| CN106046047B (zh) * | 2016-05-26 | 2018-10-02 | 清华大学 | 制备磷酸化丝氨酸膦酸模拟物的方法 |
| WO2023049501A1 (en) * | 2021-09-27 | 2023-03-30 | Abbratech Inc. | Compositions and methods for linear and conformational site specific antibodies and methods of making the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| DE4009848A1 (de) * | 1990-03-27 | 1991-10-02 | Boehringer Mannheim Gmbh | Verfahren zum nachweis von phosphoryliertes tyrosin enthaltenden proteinen |
| AU4281393A (en) * | 1992-04-10 | 1993-11-18 | Dana-Farber Cancer Institute, Inc. | Activation-state-specific phosphoprotein immunodetection |
| WO1994018324A2 (en) * | 1993-02-12 | 1994-08-18 | The Salk Institute For Biological Studies | Phospho-specific antibodies against transcription factors, more specifically against a creb derived peptide |
| US6495356B1 (en) * | 1999-11-30 | 2002-12-17 | The Regents Of The University Of California | Beryllofluoride analogues of acyl phosphate polypeptides |
-
1999
- 1999-01-25 US US09/236,415 patent/US6309863B1/en not_active Expired - Lifetime
-
2000
- 2000-01-25 AT AT00914437T patent/ATE324382T1/de not_active IP Right Cessation
- 2000-01-25 BR BR0008977-0A patent/BR0008977A/pt not_active IP Right Cessation
- 2000-01-25 AU AU35828/00A patent/AU767969B2/en not_active Ceased
- 2000-01-25 JP JP2000594838A patent/JP3891542B2/ja not_active Expired - Fee Related
- 2000-01-25 NZ NZ512868A patent/NZ512868A/en unknown
- 2000-01-25 WO PCT/US2000/001796 patent/WO2000043422A1/en active IP Right Grant
- 2000-01-25 MX MXPA01007323A patent/MXPA01007323A/es not_active IP Right Cessation
- 2000-01-25 IL IL14447100A patent/IL144471A0/xx active IP Right Grant
- 2000-01-25 DE DE60027542T patent/DE60027542T2/de not_active Expired - Lifetime
- 2000-01-25 CA CA2360511A patent/CA2360511C/en not_active Expired - Fee Related
- 2000-01-25 UA UA2001075343A patent/UA73109C2/uk unknown
- 2000-01-25 HU HU0105309A patent/HUP0105309A3/hu unknown
- 2000-01-25 EP EP00914437A patent/EP1147137B9/en not_active Expired - Lifetime
-
2001
- 2001-07-04 ZA ZA200105520A patent/ZA200105520B/en unknown
- 2001-07-19 IL IL144471A patent/IL144471A/en not_active IP Right Cessation
- 2001-07-24 NO NO20013636A patent/NO20013636L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0105309A2 (hu) | 2002-04-29 |
| DE60027542D1 (de) | 2006-06-01 |
| IL144471A (en) | 2006-06-11 |
| ZA200105520B (en) | 2002-01-17 |
| JP3891542B2 (ja) | 2007-03-14 |
| CA2360511A1 (en) | 2000-07-27 |
| IL144471A0 (en) | 2002-05-23 |
| BR0008977A (pt) | 2002-02-13 |
| EP1147137B9 (en) | 2006-11-02 |
| MXPA01007323A (es) | 2002-06-04 |
| NO20013636L (no) | 2001-09-19 |
| EP1147137A4 (en) | 2004-12-29 |
| US6309863B1 (en) | 2001-10-30 |
| CA2360511C (en) | 2012-04-10 |
| AU767969B2 (en) | 2003-11-27 |
| JP2003517451A (ja) | 2003-05-27 |
| HUP0105309A3 (en) | 2004-09-28 |
| WO2000043422A1 (en) | 2000-07-27 |
| DE60027542T2 (de) | 2007-05-03 |
| ATE324382T1 (de) | 2006-05-15 |
| NZ512868A (en) | 2003-11-28 |
| NO20013636D0 (no) | 2001-07-24 |
| EP1147137A1 (en) | 2001-10-24 |
| EP1147137B1 (en) | 2006-04-26 |
| AU3582800A (en) | 2000-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73109C2 (en) | Method for generating polyclonal antibodies and method for generating monoclonal antibodies specifically incorporated into polypeptide phosphorylated to definite amino acid | |
| Agnello et al. | Evidence for a subset of rheumatoid factors that cross-react with DNA-histone and have a distinct cross-idiotype. | |
| US20090297546A1 (en) | Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1 | |
| US6375949B1 (en) | Monoclonal antibody recognizing serum amyloid A | |
| US6818408B2 (en) | Monoclonal antibody recognizing phosphatidylinositol-3,4,5-triphosphate | |
| WO2007133689A2 (en) | Reagents for the detection of protein acetylation signaling pathways | |
| CN108148124A (zh) | 一种人hnrpa0多肽及其抗体制备方法 | |
| Muller et al. | [12] Use of antihistone antibodies with nucleosomes | |
| Weber et al. | Fine specificity and idiotype expression of antiphosphorylcholine IgE and IgG antibodies | |
| Horiguchi et al. | Production and characterization of monoclonal antibodies to Clostridium perfringens enterotoxin | |
| Jemmerson et al. | Analysis of a complex antigenic site on horse cytochrome c | |
| EP0415557B1 (en) | Separation of anti-metal chelate antibodies | |
| Bruderer et al. | Characterization of the group I and group II antibody response against PC-KLH in normal and T15 idiotype-suppressed BALB/c mice. | |
| Coetzer et al. | Localization of an immunoinhibitory epitope of the cysteine proteinase, cathepsin L | |
| JP5448424B2 (ja) | ヒトＩｇＧのＦｃを含有するタンパク質の測定試薬 | |
| Vlug et al. | Monoclonal antibodies against IgG subclasses | |
| Czernik et al. | Phosphorylation state-specific antibodies | |
| JP3397066B2 (ja) | 免疫学的測定方法を用いたアポ蛋白ｅフェノタイプの同定方法 | |
| Endo et al. | A Novel Epitope (Pentapeptide) in the Human Hemoglobin β Chain | |
| Hasnaoui et al. | Production and properties of monoclonal antibodies against human IgG isotypes | |
| JP3849001B2 (ja) | 抗−２′−デオキシシチジン抗体並びにその製造及び使用 | |
| de Lange et al. | Monoclonal antibodies to immunoglobulin allotypes: specificity and reactivity in haemagglutination and ELISA techniques | |
| Di Modugno et al. | Isolation, characterization, and comparison of antipeptide and antiprotein rabbit antibodies to the p-isoform of glutathione S-transferase | |
| Macmillan | Syndrome Toxin Produced by Staphylococcus aureus | |
| CA3179958A1 (en) | Reagents and methods for antibody sequencing |